EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 / No 6-7 (Juin–Juillet 2005) Med Sci (Paris), 21 6-7 (2005) 627-633 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Number 6-7, Juin–Juillet 2005
Page(s) 627 - 633
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005216-7627
Published online 15 June 2005
  1. Grateau G, Benson MD, Delpech M. Les amyloses. Paris : Flammarion Médecine-Sciences, 2000 : 580 p. [Google Scholar]
  2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337 : 898–909. [Google Scholar]
  3. Grateau G. Amyloses. In : Kahn MF, Peltier O, Meyer O, Piette JC, eds. Les maladies systémiques. Paris : Flammarion Médecine-Sciences, 2000 : 1279–308. [Google Scholar]
  4. Carter DB, Chou KC. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol Aging 1998; 19: 37–40. [Google Scholar]
  5. Kaplan B, Shtrasburg S, Pras M. Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003; 56 : 86–90. [Google Scholar]
  6. Baltz ML, Caspi D, Evans DJ, et al. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66 : 691–700. [Google Scholar]
  7. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11 : 649–55. [Google Scholar]
  8. Sipe JD, Ed. Amyloid proteins: the beta sheet conformation and disease. Weinheim: Wiley-VCH, 2005 (sous presse). [Google Scholar]
  9. Canet D, Sunde M, Last AM, et al. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 1999; 38 : 6419–27. [Google Scholar]
  10. Hamilton JA, Benson MD. Transthyretin: A review from a structural perspective. Cell Mol Life Sci 2001; 58 : 1–31. [Google Scholar]
  11. Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA 1974; 71 : 4864–8. [Google Scholar]
  12. O’Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279 : 17490–9. [Google Scholar]
  13. Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004; 43 : 7365–81. [Google Scholar]
  14. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27 : 527–33. [Google Scholar]
  15. Niraula TN, Konno T, Li H, et al. Pressure-dissociable reversible assembly of intrinsically denatured lysozyme is a precursor for amyloid fibrils. Proc Natl Acad Sci USA 2004; 101 : 4089–93. [Google Scholar]
  16. Korenaga T, Fu X, Xing Y, et al. Tissue distribution, biochemical properties, and transmission of mouse Type A AApoAII amyloid fibrils. Am J Pathol 2004; 164 : 1597–606. [Google Scholar]
  17. Lundmark K, Westermark GT, Nystrom S, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 2002; 99 : 6979–84. [Google Scholar]
  18. Mudher A, Lovestone S. Alzheimer’s disease : do tauists and baptists finally shake hands ? Trends Neurosci 2002; 25 : 22–6. [Google Scholar]
  19. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 2004; 1019 : 1–4. [Google Scholar]
  20. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300 : 486–9. [Google Scholar]
  21. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279 : 46363–6. [Google Scholar]
  22. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94 : 1008–10. [Google Scholar]
  23. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140 : 85–93. [Google Scholar]
  24. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17 : 615–20. [Google Scholar]
  25. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004; 47 : 355–74. [Google Scholar]
  26. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4’-iodo-4’deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002; 9 : 24–30. [Google Scholar]
  27. Cardoso I, Merlini G, Saraiva MJ. 4’-iodo-4’-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J 2003; 17 : 803–9. [Google Scholar]
  28. Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355 : 192–7. [Google Scholar]
  29. Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306 : 865–9. [Google Scholar]
  30. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nat Med 1995; 1 : 143–8. [Google Scholar]
  31. Kisilevsky R, Szarek WA, Ancsin JB, et al. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 2004; 164 : 2127–37. [Google Scholar]
  32. Pepys MB, Herbert J, Hutchinson WL. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417 : 254–9. [Google Scholar]
  33. Dumoulin M, Dobson CM. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 2004; 86 : 589–600. [Google Scholar]
  34. O’Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002; 99 : 1485–90. [Google Scholar]
  35. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000; 157 : 1239–46. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.